Specifically, CAR T-cell therapy targets tumor surface molecules such as epidermal growth factor receptor variant III (EGFR variant III) [57], interleukin 13 receptor subunit alpha 2 (IL13Rα2) [58], and human epidermal growth factor receptor 2 (HER2) [59]. This evidence concerns the gene IL13RA2 and neoplasm.